Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon

Yvonne E. Chiu; Beth A. Drolet; Francine Blei; Manuel Carcao; Jason Fangusaro; Michael E. Kelly; Alfons Krol; Sabra Lofgren; Anthony J. Mancini; Denise W. Metry; Michael Recht; Robert A. Silverman; Wynnis L. Tom; Elena Pope

doi:10.1002/pbc.24103

Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon

Yvonne E. Chiu^*, Beth A. Drolet, Francine Blei, Manuel Carcao, Jason Fangusaro, Michael E. Kelly, Alfons Krol, Sabra Lofgren, Anthony J. Mancini, Denise W. Metry, Michael Recht, Robert A. Silverman, Wynnis L. Tom, Elena Pope

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

107 Scopus citations

Abstract

Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP). We report 11 patients treated with propranolol for KHE and the related variant tufted angioma (TA), six of whom also had KMP. The varied responses to treatment, with only 36% responding in our series, demonstrate the need for further study of this medication before routine use for these indications.

Original language	English (US)
Pages (from-to)	934-938
Number of pages	5
Journal	Pediatric Blood and Cancer
Volume	59
Issue number	5
DOIs	https://doi.org/10.1002/pbc.24103
State	Published - Nov 2012

Funding

Keywords

Kaposiform hemangioendothlioma
Kasabach-Merritt
Propranolol
Treatment
Tufted angioma
Vascular tumor

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.24103

Cite this

Chiu, Y. E., Drolet, B. A., Blei, F., Carcao, M., Fangusaro, J., Kelly, M. E., Krol, A., Lofgren, S., Mancini, A. J., Metry, D. W., Recht, M., Silverman, R. A., Tom, W. L., & Pope, E. (2012). Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatric Blood and Cancer, 59(5), 934-938. https://doi.org/10.1002/pbc.24103

@article{256593845e494cb7a9ed01ab1946b377,

title = "Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon",

abstract = "Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP). We report 11 patients treated with propranolol for KHE and the related variant tufted angioma (TA), six of whom also had KMP. The varied responses to treatment, with only 36% responding in our series, demonstrate the need for further study of this medication before routine use for these indications.",

keywords = "Kaposiform hemangioendothlioma, Kasabach-Merritt, Propranolol, Treatment, Tufted angioma, Vascular tumor",

author = "Chiu, {Yvonne E.} and Drolet, {Beth A.} and Francine Blei and Manuel Carcao and Jason Fangusaro and Kelly, {Michael E.} and Alfons Krol and Sabra Lofgren and Mancini, {Anthony J.} and Metry, {Denise W.} and Michael Recht and Silverman, {Robert A.} and Tom, {Wynnis L.} and Elena Pope",

year = "2012",

month = nov,

doi = "10.1002/pbc.24103",

language = "English (US)",

volume = "59",

pages = "934--938",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "5",

}

Chiu, YE, Drolet, BA, Blei, F, Carcao, M, Fangusaro, J, Kelly, ME, Krol, A, Lofgren, S, Mancini, AJ, Metry, DW, Recht, M, Silverman, RA, Tom, WL & Pope, E 2012, 'Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon', Pediatric Blood and Cancer, vol. 59, no. 5, pp. 934-938. https://doi.org/10.1002/pbc.24103

TY - JOUR

T1 - Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon

AU - Chiu, Yvonne E.

AU - Drolet, Beth A.

AU - Blei, Francine

AU - Carcao, Manuel

AU - Fangusaro, Jason

AU - Kelly, Michael E.

AU - Krol, Alfons

AU - Lofgren, Sabra

AU - Mancini, Anthony J.

AU - Metry, Denise W.

AU - Recht, Michael

AU - Silverman, Robert A.

AU - Tom, Wynnis L.

AU - Pope, Elena

PY - 2012/11

Y1 - 2012/11

N2 - Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP). We report 11 patients treated with propranolol for KHE and the related variant tufted angioma (TA), six of whom also had KMP. The varied responses to treatment, with only 36% responding in our series, demonstrate the need for further study of this medication before routine use for these indications.

AB - Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP). We report 11 patients treated with propranolol for KHE and the related variant tufted angioma (TA), six of whom also had KMP. The varied responses to treatment, with only 36% responding in our series, demonstrate the need for further study of this medication before routine use for these indications.

KW - Kaposiform hemangioendothlioma

KW - Kasabach-Merritt

KW - Propranolol

KW - Treatment

KW - Tufted angioma

KW - Vascular tumor

UR - http://www.scopus.com/inward/record.url?scp=84866169497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866169497&partnerID=8YFLogxK

U2 - 10.1002/pbc.24103

DO - 10.1002/pbc.24103

M3 - Article

C2 - 22648868

AN - SCOPUS:84866169497

SN - 1545-5009

VL - 59

SP - 934

EP - 938

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 5

ER -

Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this